Assessment of the Efficacy of Therapies Following Venetoclax Discontinuation in CLL Reveals BTK Inhibition as an Effective Strategy
Anthony R. Mato(Memorial Sloan Kettering Cancer Center), Colleen Dorsey(Memorial Sloan Kettering Cancer Center), Brian T. Hill(Cleveland Clinic), Thomas D. Rodgers(University of Rochester Medical Center), Allison Winter(Cleveland Clinic), Nicole Lamanna(Memorial Sloan Kettering Cancer Center), Alan P Skarbnik(Novant Health), Talha Munir(Leeds Teaching Hospitals NHS Trust), Catherine C. Coombs(Memorial Sloan Kettering Cancer Center), Craig A. Portell, Kate J. Whitaker(Memorial Sloan Kettering Cancer Center), Guilherme Fleury Perini(Hospital Israelita Albert Einstein), Jeffrey J. Pu(SUNY Upstate Medical University), Pratik Shah(Northwell Health), Othman Salim Akhtar(Roswell Park Comprehensive Cancer Center), Ryan Jacobs(Levine Cancer Institute), Nicolás Martínez‐Calle(Nottingham University Hospitals NHS Trust), Krista M. Isaac, Danielle M. Brander(Duke University), Lindsey E. Roeker(Memorial Sloan Kettering Cancer Center), Rachael Pocock(The London College), Helen Parry(University of Birmingham), Pallawi Torka(Roswell Park Comprehensive Cancer Center), Mazyar Shadman(University of Washington), Julie M. Goodfriend(Memorial Sloan Kettering Cancer Center), Paul M. Barr(Memorial Sloan Kettering Cancer Center), Sirin Khajavian(Fred Hutch Cancer Center), Joanna Rhodes(Roswell Park Comprehensive Cancer Center), Andrew D. Zelenetz(Memorial Sloan Kettering Cancer Center), Andrea Sitlinger(Duke Medical Center), Amber C. King(Memorial Sloan Kettering Cancer Center), Hanna Weissbrot(Columbia University Irving Medical Center), Jacqueline C. Barrientos(Northwell Health), Michael Y. Choi(University of California San Diego), Chaitra S. Ujjani(Fred Hutch Cancer Center), Stephen J. Schuster(UPMC Hillman Cancer Center), Christine Garcia(University of Pittsburgh), Bita Fakhri(University of California, San Francisco), Christopher P. Fox(Nottingham University Hospitals NHS Trust), Erica B. Bhavsar(St James's University Hospital), Ariel Grajales‐Cruz(Moffitt Cancer Center), Timothy Voorhees(University of North Carolina at Chapel Hill), Jason C. Lee(Columbia University Irving Medical Center), Javier Pinilla‐Ibarz(Moffitt Cancer Center), Chadi Nabhan(University of Chicago), Satyen H. Gohil(Broad Institute), John M. Pagel, Maryam Sarraf Yazdy(Georgetown University), Kentson Lam(University of California San Diego), Neil A. Bailey
Cited by 115
Related Papers
Genetics and Pathogenesis of Diffuse Large B-Cell Lymphoma
|New England Journal of Medicine|2018|2.3k
Idelalisib and Rituximab in Relapsed Chronic Lymphocytic Leukemia
|New England Journal of Medicine|2014|1.7k
Ibrutinib versus Ofatumumab in Previously Treated Chronic Lymphoid Leukemia
|New England Journal of Medicine|2014|1.6k
Ibrutinib as Initial Therapy for Patients with Chronic Lymphocytic Leukemia
|New England Journal of Medicine|2015|1.6k